Skip to main content


Liver Cancer

Featured

Quiz
True or False: Pembrolizumab is not considered a cost-effective second-line therapy for treating HCC.
News
Compared with selective internal radiotherapy, sorafenib is not unlikely cost-effective for HCC in the United States.
News
Study findings suggest pembrolizumab is not a cost-effective second-line therapy for HCC at its current price in the US.
Podcast
Brian Seal, PhD, RPh, MBA discusses results from a study which examined the lines of loco-regional therapies received…
Videos
Ghassan Abou-Alfa, MD, discusses results from a study evaluating the association between post-treatment α-fetoprotein…
Back to Top